<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Loulou Foundation 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=35326></link><description><![CDATA[Loulou Foundation 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Wed, 15 Apr 2026 07:36:34 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2020/06/12_3554238800_20200617172049_4870434576.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[CDKL5 Deficiency Disorder Voice of the Patient Report Submitted to FDA]]></title><link>https://www.newswire.co.kr/newsRead.php?no=906568</link><description><![CDATA[PHILADELPHIA--(Business Wire/Korea Newswire)--Understanding the patient voice is fundamental for therapy development. Companies need to ensure that what matters most to patients is being assessed, and regulators and payers asks for demonstration of value to support approval and reimbursement. Today, the Loulou Foundation and the International Foundation for CDKL5 Research (IFCR) are proud t...]]></description><pubDate>Thu, 18 Jun 2020 14:00:00 +0900</pubDate></item><item><title><![CDATA[‘CDKL5 결핍장애 환자들의 목소리 보고서’ FDA에 제출돼]]></title><link>https://www.newswire.co.kr/newsRead.php?no=906569</link><description><![CDATA[필라델피아--(Business Wire/뉴스와이어)--환자들의 목소리를 제대로 이해하는 것은 치료방법 개발에서 가장 중요한 측면이 된다.  기업들은 환자들에 있어 가장 중요한 것이 무엇인지를 평가하고 의약품 승인 및 약가 환불을 위해 규제 당국과 보험사들이 요구하는 가치 입증의 의무를 갖고 있다. 룰루 재단(Loulou Foundation)과 CDKL5 연구를 위한 국제 재단(International Foundation for CDKL5 Research, IFCR)...]]></description><pubDate>Thu, 18 Jun 2020 14:00:00 +0900</pubDate></item></channel></rss>